WO2013048174A3 - Kit for diagnosing pancreatic adenocarcinoma, comprising means for measuring ca19-9, cathepsin d and matrix metalloproteinase-7 - Google Patents

Kit for diagnosing pancreatic adenocarcinoma, comprising means for measuring ca19-9, cathepsin d and matrix metalloproteinase-7 Download PDF

Info

Publication number
WO2013048174A3
WO2013048174A3 PCT/KR2012/007895 KR2012007895W WO2013048174A3 WO 2013048174 A3 WO2013048174 A3 WO 2013048174A3 KR 2012007895 W KR2012007895 W KR 2012007895W WO 2013048174 A3 WO2013048174 A3 WO 2013048174A3
Authority
WO
WIPO (PCT)
Prior art keywords
pancreatic adenocarcinoma
kit
diagnosing pancreatic
cathepsin
measuring
Prior art date
Application number
PCT/KR2012/007895
Other languages
French (fr)
Korean (ko)
Other versions
WO2013048174A2 (en
Inventor
이수연
김종원
박형두
이종균
Original Assignee
사회복지법인 삼성생명공익재단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사회복지법인 삼성생명공익재단 filed Critical 사회복지법인 삼성생명공익재단
Publication of WO2013048174A2 publication Critical patent/WO2013048174A2/en
Publication of WO2013048174A3 publication Critical patent/WO2013048174A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to a reagent for diagnosing pancreatic adenocarcinoma, comprising a means for measuring the blood concentration of CA19-9, cathepsin D and matrix metalloproteinase-7, a kit for diagnosing pancreatic adenocarcinoma containing the reagent for diagnosing pancreatic adenocarcinoma, and a method for providing the information necessary for diagnosing pancreatic adenocarcinoma using the kit for diagnosing pancreatic adenocarcinoma. Early diagnosis of pancreatic adenocarcinoma is possible using the kit for diagnosing pancreatic adenocarcinoma of the present invention, and thus the kit may be widely used to more effectively treat pancreatic adenocarcinoma.
PCT/KR2012/007895 2011-09-28 2012-09-28 Kit for diagnosing pancreatic adenocarcinoma, comprising means for measuring ca19-9, cathepsin d and matrix metalloproteinase-7 WO2013048174A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110098548A KR101358510B1 (en) 2011-09-28 2011-09-28 A Kit for Diagnosing Pancreatic Adenocarcinoma Comprising Measuring Means of Cathepsin D and MMP-7
KR10-2011-0098548 2011-09-28

Publications (2)

Publication Number Publication Date
WO2013048174A2 WO2013048174A2 (en) 2013-04-04
WO2013048174A3 true WO2013048174A3 (en) 2013-05-23

Family

ID=47996643

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/007895 WO2013048174A2 (en) 2011-09-28 2012-09-28 Kit for diagnosing pancreatic adenocarcinoma, comprising means for measuring ca19-9, cathepsin d and matrix metalloproteinase-7

Country Status (2)

Country Link
KR (1) KR101358510B1 (en)
WO (1) WO2013048174A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3159695A3 (en) * 2013-06-20 2017-07-05 The Trustees of The University of Pennsylvania Methods for diagnosing pancreatic cancer
KR101665165B1 (en) * 2013-12-04 2016-10-12 단국대학교 산학협력단 Novel RNA aptamers and the Uses thereof
KR20150129932A (en) * 2014-05-12 2015-11-23 연세대학교 산학협력단 A kit for pancreatic cancer diagnosis comprising complememt factor b-specific binding antibody
CN114250298A (en) * 2020-09-23 2022-03-29 中国医学科学院北京协和医院 DNA methylation marker of pancreatic ductal adenocarcinoma and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126243A (en) * 1982-08-09 1992-06-30 Centocor, Inc. Immunoassay for carbohydrate antigenic determinant

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126243A (en) * 1982-08-09 1992-06-30 Centocor, Inc. Immunoassay for carbohydrate antigenic determinant

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JI KON RYU ET AL.: "Molecular Diagnosis and Tumor Markers in Pancreatic Cancer", KOREAN JOURNAL OF HBP SURGERY, vol. 8, no. 2, June 2004 (2004-06-01), pages 69 - 75, XP003031635 *
LUCIE E. JONES ET AL.: "Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: Increased expression of matrix metalloproteinase 7 predicts poor survival", CLINICAL CANCER RESEARCH, vol. 10, no. 8, 2004, pages 2832 - 2845, XP003031633 *
MAIKEN THYREGOD JOERGENSEN ET AL.: "Comparison of Circulating MMP-9, TIMP-1 and CA19-9 in the Detection of Pancreatic Cancer", ANTICANCER RESEARCH, vol. 30, no. 2, 2010, pages 587 - 592, XP003031632 *
RU CHEN ET AL.: "Quantitative Proteomics Analysis Reveals That Proteins Differentially Expressed in Chronic Pancreatitis Are Also Frequently Involved in Pancreatic Cancer", MOLECULAR & CELLULAR PROTEOMICS, vol. 6, no. 8, 2007, pages 1331 - 1342, XP003031634 *

Also Published As

Publication number Publication date
KR101358510B1 (en) 2014-02-06
KR20130034505A (en) 2013-04-05
WO2013048174A2 (en) 2013-04-04

Similar Documents

Publication Publication Date Title
WO2013066369A3 (en) Methods for detecting graft-versus-host disease
WO2013190075A3 (en) Specific biomarkers for hepatocellular carcinoma (hcc)
WO2010091049A3 (en) Diagnosis and treatment of cancer
WO2012021407A3 (en) Biomarkers for stroke
WO2009085234A3 (en) Use of micro-rna as a biomarker of immunomodulatory drug activity
AU2012356133A8 (en) A rapid quantitative assay to measure CFTR function in a primary intestinal culture model
WO2012149493A3 (en) Hsp90 combination therapy
IL225386A (en) Method for diagnosis of cancer by detecting an ereg protein
MX2013002084A (en) Biomarkers and methods of treatment.
WO2011151252A3 (en) Means and methods for diagnosing pancreatic cancer in a subject
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2013107459A3 (en) Microrna for diagnosis of pancreatic cancer and/or prognosis of patients with pancreatic cancer by blood samples
WO2011015944A3 (en) Use of free dna as an early predictor of severity in acute pancreatitis
WO2010120942A3 (en) Histone modification patterns for clinical diagnosis and prognosis of cancer
MX2013005139A (en) A guided structured testing kit.
WO2013048174A3 (en) Kit for diagnosing pancreatic adenocarcinoma, comprising means for measuring ca19-9, cathepsin d and matrix metalloproteinase-7
AU2012339149A8 (en) Method for the diagnosis of Niemann-Pick disease
WO2013062261A3 (en) Newly identified colon cancer marker and diagnostic kit using the same
WO2011133036A3 (en) Means and methods for determining risk of cardiovascular disease
WO2013009146A3 (en) Marker for diagnosing diabetic retinopathy
GB201201766D0 (en) Method
WO2012004276A3 (en) Multiprotein biomarkers of amyotrophic lateral sclerosis in peripheral blood mononuclear cells, diagnostic methods and kits
WO2012145399A3 (en) Methods of diagnosing cancer in a patient
WO2010047938A3 (en) Mmp activation peptide detection in biological samples
WO2012034013A3 (en) Detection of rna-interacting regions in dna

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12836486

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12836486

Country of ref document: EP

Kind code of ref document: A2